Evolution of the Average Target: Cartesian Therapeutics, Inc.

Evolution of the Target Price: Cartesian Therapeutics, Inc.

Changes in Analyst Recommendations: Cartesian Therapeutics, Inc.

e5e7c15aa4507bd6157fcb89643ef4bb.X2VsQVGwKBrL5N5DFWLvxWDVvtJbm5_vyAPMOUytq6c.Hj8hOyHSXCOJqZZ3OCe5rlS4_4Y8zqaF8Fb7fHnZ5esaVycvHdRbQKaHmw~1ddb1407c94e36734cea4df637eb31c6
21/10/25 Cartesian Therapeutics, Inc. Announces Departure of Chief Scientific Officer, Christopher Jewell, Ph.D., Effective November 14, 2025 CI
09/07/25 Wedbush Initiates Cartesian Therapeutics at Outperform With $38 Price Target MT
19/12/24 BTIG Research Initiates Coverage on Cartesian Therapeutics With Buy Rating, $42 Price Target MT
06/08/24 TD Cowen Starts Cartesian Therapeutics With Buy Rating MT
03/07/24 Canaccord Genuity Raises Price Target on Cartesian Therapeutics to $43 From $38, Maintains Buy Rating MT
03/07/24 HC Wainwright Adjusts Price Target on Cartesian Therapeutics to $49 From $54, Maintains Buy Rating MT
02/07/24 Oppenheimer Downgrades Cartesian Therapeutics to Market Perform From Outperform; Shares Tumble MT
04/06/24 Oppenheimer Initiates Cartesian Therapeutics With Outperform Rating, $50 Price Target MT
24/05/24 Mizuho Securities Starts Cartesian Therapeutics With Buy Rating MT
23/04/24 Leerink Partners Starts Cartesian Therapeutics With Outperform Rating, $39 Price Target MT
18/08/23 Mizuho Trims Price Target on Selecta Biosciences to $3 From $4, Maintains Buy Rating MT
18/08/23 Needham Adjusts Price Target on Selecta Biosciences to $4 From $5, Maintains Buy Rating MT
22/03/23 HC Wainwright Adjusts Price Target on Selecta Biosciences to $5 From $4, Maintains Buy Rating MT
22/03/23 Mizuho Securities Adjusts Selecta Biosciences Price Target to $4 From $5, Maintains Buy Rating MT
31/01/23 Canaccord Genuity Adjusts Selecta Biosciences Price Target to $9 From $10, Maintains Buy Rating MT
21/06/22 HC Wainwright Adjusts Price Target on Selecta Biosciences to $4 From $6, Reiterates Buy Rating MT
14/06/22 Needham Adjusts Price Target on Selecta Biosciences to $5 From $6, Reiterates Buy Rating MT
06/06/22 SVB Securities Initiates Selecta Biosciences at Outperform With $7 Price Target MT
15/06/21 Selecta Biosciences : BTIG Starts Selecta Biosciences at Buy With $10 Price Target MT
12/03/21 Selecta Biosciences : William Blair Upgrades Selecta Biosciences to Outperform from Market Perform MT
26/01/21 Selecta Biosciences : Mizuho Upgrades Selecta Biosciences to Buy From Neutral, Adjusts Price Target to $8 From $2.50 MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+319.26%
+16.92%
+17.96%
+66.29%
+15.47%
+23.62%
+8.57%
+18.41%
-8.01%
+62.99%
Average +54.15%
Weighted average by Cap. +23.11%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
8.030USD
Average target price
33.67USD
Spread / Average Target
+319.26%
High Price Target
44.00USD
Spread / Highest target
+447.95%
Low Price Target
16.00USD
Spread / Lowest Target
+99.25%

Analyst Consensus Detail

Consensus revision (last 18 months)

Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
  1. Stock Market
  2. Stocks
  3. RNAC Stock
  4. Consensus Cartesian Therapeutics, Inc.
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!